Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea®1Agreement builds on the proven and successful collaboration of ...
FYB203 (aflibercept) approved in the UK for the treatment of neovascular age ... of Teva Pharmaceuticals Limited Formycon AG (FSE: FYB) is a leading, independent developer of high-quality ...
In a report released on March 27, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Formycon AG (FYB – Research Report), with a price target of €50.00. The company’s shares ...
The biosimilar received marketing authorization from the EMA and the FDA in September 2024, and from Health Canada and the UK's MHRA in January 2025. Formycon AG (FSE: FYB) is a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback